# AT2R antagonist 1

| | |
|---|---|
| **Cat. No.:** | HY-146410 |
| **CAS No.:** | 2709031-17-2 |
| **Molecular Formula:** | $C_{23}H_{30}N_4O_4S_2$ |
| **Molecular Weight:** | 490.64 |
| **Target:** | Angiotensin Receptor |
| **Pathway:** | GPCR/G Protein |
| **Storage:** | Please store the product under the recommended conditions in the Certificate of Analysis. |



## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | AT2R antagonist 1 (compound 21) is a potent and high selective AT2R (angiotensin II AT2 receptor) ligand. AT2R antagonist 1 exhibits a fair AT2R affinity, with a $K_i$ of 29 nM. AT2R antagonist 1 also inhibits common agent-metabolizing CYP enzymes. AT2R antagonist 1 shows high stability in human, rat and mouse liver microsomes[1]. |
| **$IC_{50}$ & Target** | AT2 Receptor |
| **In Vitro** | AT2R antagonist 1 (compound 21) exhibits a negligible inhibition of CYP 3A (5%) and a very low tendency to inhibit CYP 2D6 (12%), 2C8 (26%), 2C9 (23%) and 2B6 (24%)[1].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

## REFERENCES

[1]. Bolteau R, et al. Quinazoline and phthalazine derivatives as novel melatonin receptor ligands analogues of agomelatine. Eur J Med Chem. 2020 Mar 1;189:112078.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA